时珍国医国药2025，Vol.36Issue(8)：1459-1465,7.DOI:10.70976/j.1008-0805.SZGYGY-2025-0810
基于上皮源细胞因子探究摄涕止鼽方治疗变应性鼻炎(肺气虚寒型)的临床疗效与作用机制
Exploring the clinical efficacy and mechanism of Sheti Zhiqiu Formula(摄涕止鼽方)in trea-ting allergic rhinitis(lung qi deficiency and cold type)based on epithelial-derived cytokines
摘要
Abstract
Objective To observe the clinical efficacy of Sheti Zhiqiu Formula(摄涕止鼾方,STZQ)in treating allergic rhinitis(AR)of lung qi deficiency and cold and explore the mechanism of STZQ from the perspective of epithelial-derived cytokines.Methods Sixty AR patients(lung qi deficiency and cold type)were randomly divided into the experimental group and control group,with 30 cases in each group.The two groups were treated with STZQ and placebo three times daily for 4 weeks.Total nasal symptom score(TNSS),indi-vidual nasal symptom score(INSS),total nasal non-symptom score(TNNSS),traditional Chinese medicine(TCM)syndrome score,and rhinoconjunctivitis quality of life questionnaire(RQLQ)of two groups were recorded before and after treatment.Nasal lavage fluid was collected to measure levels of TSLP,IL-25,IL-5,Eotaxin-1,and IL-8 by ELISA.Clinical efficacy and mechanism of STZQ in treating AR were explored through clinical studies.Results After treatment,both groups showed reduced TNSS,INSS,TNNSS,RQLQ,and TCM syndrome scores compared to those of before treatment(P<0.05).No significant differences in TNSS,INSS,TNNSS and RQLQ of post-treatment exist between the two groups(P>0.05),while the trial group had lower TCM syndrome scores than the control group(P<0.05).The levels of TSLP,IL-25,IL-5,Eotaxin-1,and IL-8 in the experimental group were decreased after treatment(P<0.05).In the control group,IL-5 levels of after treatment was decreased(P<0.05),while levels of TSLP,IL-25,Eotaxin-1,and IL-8 showed no significant changes before and after treatment(P>0.05).No significant difference in post-treat-ment IL-5 levels exist between the two groups(P>0.05),but the trial group had lower levels of TSLP,IL-25,Eotaxin-1,and IL-8 than those in the control group(P<0.05).The trial group exhibited higher total efficacy(P<0.05).No severe adverse reactions occurred in two groups.Conclusion STZQ demonstrates definite clinical efficacy in treating AR(lung qi deficiency and cold type),and its mechanism may lie in ameliorating AR by regulating Th2 via epithelial-derived cytokines.关键词
变应性鼻炎/摄涕止鼽方/上皮源细胞因子/辅助型T细胞2Key words
Allergic rhinitis/Sheti Zhiqiu Formula(摄涕止鼾方)/Epithelial-derived cytokines/T helper type 2(Th2)cells分类
医药卫生引用本文复制引用
刘礼莎,罗超,任全伟,王芳,康后鑫,彭顺林..基于上皮源细胞因子探究摄涕止鼽方治疗变应性鼻炎(肺气虚寒型)的临床疗效与作用机制[J].时珍国医国药,2025,36(8):1459-1465,7.基金项目
成都市科技局技术创新研发项目(2022-YF05-01373-SN) （2022-YF05-01373-SN）
四川省中医药管理局项目(2021MS098) （2021MS098）
成都市科技局技术创新研发项目(2021-YF05-01940-SN) （2021-YF05-01940-SN）
